Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.17 Insider Own7.20% Shs Outstand43.40M Perf Week28.70%
Market Cap60.33M Forward P/E- EPS next Y-1.90 Insider Trans-36.15% Shs Float39.23M Perf Month45.55%
Income-158.70M PEG- EPS next Q-0.63 Inst Own87.20% Short Float7.52% Perf Quarter-72.14%
Sales16.20M P/S3.72 EPS this Y-61.10% Inst Trans-5.13% Short Ratio1.69 Perf Half Y-77.83%
Book/sh3.32 P/B0.42 EPS next Y34.70% ROA-68.90% Target Price3.83 Perf Year-90.72%
Cash/sh2.66 P/C0.52 EPS next 5Y- ROE-93.20% 52W Range0.74 - 15.98 Perf YTD-81.19%
Dividend- P/FCF- EPS past 5Y- ROI-55.10% 52W High-91.30% Beta0.83
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin37.20% 52W Low87.84% ATR0.19
Employees169 Current Ratio3.20 Sales Q/Q59.50% Oper. Margin- RSI (14)55.18 Volatility18.07% 13.25%
OptionableYes Debt/Eq0.23 EPS Q/Q-19.80% Profit Margin- Rel Volume1.43 Prev Close1.63
ShortableYes LT Debt/Eq0.22 EarningsAug 08 AMC Payout- Avg Volume1.74M Price1.39
Recom2.00 SMA2027.72% SMA504.42% SMA200-71.69% Volume2,494,716 Change-14.72%
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Sep-19-19 07:40PM  IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -14.72%
01:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS ACCESSWIRE
11:30AM  DEADLINE: Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Sep-18-19 07:51PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contact the Firm GlobeNewswire -9.44%
05:45PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:23PM  A Look At Benzinga Pro's Most-Searched Tickers For September 18, 2019 Benzinga
10:42AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-17-19 08:49PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire +63.64%
02:45PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:29PM  A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019 Benzinga
11:15AM  Why Microcap Biotech Aclaris Is Rallying Benzinga
07:23AM  The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga
07:00AM  Aclaris Therapeutics to Hold R&D Day GlobeNewswire
Sep-16-19 04:55PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +6.80%
04:15PM  Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) GlobeNewswire
10:41AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:38AM  ACRS NOTICE, ROSEN, A LEADING FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS ACCESSWIRE
09:35AM  UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:14AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
Sep-14-19 07:02AM  SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-13-19 03:45PM  Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
03:15PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 GlobeNewswire
10:05AM  SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE
Sep-12-19 09:10PM  IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
06:20PM  GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS Business Wire
02:52PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire
Sep-11-19 09:20PM  IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:15AM  INVESTOR ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE
Sep-10-19 07:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire +7.69%
06:20PM  SEPTEMBER DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:00PM  NATIONALLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM ACRS GlobeNewswire
11:36AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
10:07AM  Why Aclaris is laying off half of its staff American City Business Journals
09:15AM  ACRS DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Sep-09-19 12:55PM  Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders Business Wire
11:25AM  UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:47AM  Chester County biopharmaceutical firm cutting 86 jobs American City Business Journals
Sep-06-19 10:55PM  ACRS DEADLINE: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE +9.68%
Sep-05-19 06:46PM  Pomerantz Law Firm Announces the Filing of a Class Action against Aclaris Therapeutics Inc. and Certain Officers ACRS GlobeNewswire
Sep-04-19 11:15PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
Sep-03-19 10:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Contact the Firm GlobeNewswire -5.91%
04:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
10:25AM  UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-02-19 02:00PM  HIGHLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS GlobeNewswire
Aug-29-19 11:10PM  ROSEN, A LEADING FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACCESSWIRE
01:23PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
Aug-28-19 10:00PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:05AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile
Aug-27-19 04:25PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE -5.81%
10:35AM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
08:00AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and Encourages Investors to Contact the Firm GlobeNewswire
Aug-26-19 10:11PM  ACRS: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire
05:10PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Aug-24-19 10:10AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS PR Newswire
09:40AM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In OASM, ACRS, GTT or JE To Contact The Firm Newsfile
Aug-22-19 09:05PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +13.54%
03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Aug-21-19 04:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
09:00AM  Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know Zacks
Aug-20-19 04:01PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
01:15PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:32PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
11:15AM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-19-19 03:30PM  ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ACRS ACCESSWIRE +6.52%
Aug-18-19 07:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm GlobeNewswire
Aug-17-19 08:45AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
Aug-16-19 02:38PM  Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire +9.19%
11:50AM  Aclaris Therapeutics halts marketing efforts for one of its skin disorder drugs American City Business Journals
09:40AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
Aug-15-19 11:00PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
05:38PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
10:00AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile
Aug-14-19 02:45AM  Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents -5.01%
Aug-13-19 08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
03:00PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
10:15AM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-12-19 04:00PM  ROSEN, A LEADING LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS Business Wire -5.72%
01:00PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire
Aug-11-19 07:25PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 3M Company, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm GlobeNewswire
Aug-10-19 12:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
Aug-09-19 07:00PM  ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm ACRS GlobeNewswire -9.08%
11:02AM  Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-08-19 06:20PM  Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments GlobeNewswire
Aug-07-19 04:00PM  ACLARIS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Southern District of New York against Aclaris Therapeutics, Inc. GlobeNewswire
02:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE
10:45AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
10:18AM  Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Salary Justified? Simply Wall St.
Aug-06-19 07:49PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. Business Wire
04:40PM  Zhang Investor Law Announces Securities Class Action Lawsuit Aclaris Therapeutics, Inc. ACRS GlobeNewswire
04:30PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
03:55PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
10:51AM  Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance Zacks
Aug-05-19 09:30PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, 3M Company, and Aclaris Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire
07:15PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. Business Wire
07:08PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire
04:55PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm ACCESSWIRE
10:00AM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-03-19 08:05AM  IMPORTANT INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerJun 27Sale2.69699,4751,882,077964,101Jul 01 05:01 PM
Flynn James E10% OwnerJun 26Sale4.501,7047,6711,072,775Jun 26 05:52 PM
Flynn James E10% OwnerJun 25Sale4.5151,484232,1361,073,127Jun 25 06:31 PM
Flynn James E10% OwnerJun 24Sale4.5263,240286,0031,083,761Jun 25 06:31 PM
Flynn James E10% OwnerJun 21Sale4.62339,5371,567,0991,096,824Jun 25 06:31 PM
Flynn James E10% OwnerMay 10Sale6.05180,5651,092,2741,166,959May 13 05:24 PM
Flynn James E10% OwnerMay 09Sale6.16434,1452,673,2481,238,828May 13 05:24 PM
Mehra AnandDirectorOct 22Buy10.75372,0934,000,0001,911,573Oct 23 07:13 PM
Tullman Stephen A.DirectorOct 04Buy14.007,10099,370177,457Oct 05 04:37 PM